Testing and Linkage to Care for IDUs in Kenya (TLC-IDU Kenya); HCV Among PWIDs in Kenya: A Supplement to the TLC-IDU Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9,449
- 试验地点
- 1
- 主要终点
- Linkage to care and time to ART
研究概览
简要总结
Testing and Linkage to Care for Injecting Drug Users in Kenya:
Interventions for people who inject drugs (PWID) in sub-Saharan African have been almost entirely absent, despite the fact that in countries like Kenya they contribute a growing proportion of incident HIV infections. This study will leverage a historic decision in Kenya to launch needle exchange program (NSP) and related services for this most-at-risk population (MARP). The investigators will use this NSP/MARP platform to seek out PWID, deliver rapid HIV testing, point of care CD4 count and link to ART using peer case managers, and evaluate community viral load impact using a stepped wedge cluster-randomized design. Lessons learned will have important applicability throughout sub-Saharan African.
HCV Among PWID in Kenya: A Supplement to the TLC-IDU study:
The prevalence of HCV in Kenya, where an increasing number of people who inject drugs (PWID) live and are becoming HIV- as well as HCV-infected, has not been defined. We will establish HCV prevalence among PWID in Nairobi, Western, and Coastal region by adding HCV rapid and confirmatory tests in our parent PWID study (TLC-IDU Kenya); deliver appropriate counseling and treatment options to those eligible; collect HCV treatment adherence data; and disseminate study findings. These data will provide novel and relevant information about HCV and HIV co-infection in Kenya among PWID that will be immediately applicable in terms of public health impact to national and regional HCV testing, counseling, and clinical management policy.
详细描述
Testing and Linkage to Care for Injecting Drug Users in Kenya
The purpose of the study will be to leverage the GoK's first-ever needle and syringe program, to implement the HIV seek, test, treat, and retain paradigm among PWID, whose parenteral and sexual transmission networks amplify HIV epidemics. Study innovations include: (1) use of a stepped wedge trial design; (2) intent to track community viral load in a low-income country setting; (3) use of rapid CD4 assays to reduce time from HIV diagnosis to ART initiation; and (4) use of conditional cash transfers to support peer case management of participant HIV treatment retention.
Aim 1: Evaluate seek test treat retain using a stepped wedge cluster-randomized design. Clusters will be the planned NSP service sites. The investigators will initiate respondent-driven sampling (RDS) to reach PWID in Nairobi, Western region and coastal Mombasa (including Malindi) for baseline HIV-1 prevalence determination, then collect waves of study data as service sites roll out, including behavioral data. Teams will do rapid HIV and HCV testing and refer for addiction/mental health and other services (e.g., OST). HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Both peer case managers and subjects will receive small conditional cash transfers for subject's adherence to HIV care visits. Primary study outcomes will include time to successful linkage to care, time to ART, and community viral load before and after TLC-IDU initiation. 'Community viral load' will be ascertained by collecting specimens from randomly-selected HIV-positives at each of the NASCOP NSP-IDU service sites. This sampling will be done in waves over time, to document changes in infectivity (median viral load). With individual viral loads collected per site per time step (for a n= of at least 1800 viral loads in total across all sites and timewaves) the investigators will have good power to detect log10 viral load changes of 0.23 and hazard ratios of ~1.5 when comparing pre- and post-intervention period using linear mixed effects analysis.
Aim 1: Research hypothesis: Staggered rollout of a planned NSP/MARP program can be utilized to collect pre- and post intervention data that will allow assessment of impact on community viral load. Linkage to care will be higher, time to ART initiation will be reduced, and retention in care will be higher during time periods with the TLC-IDU services as compared to time periods with standard of care.
Aim 2: Conduct mathematical modeling to estimate community viral load in PWID injecting and sexual networks, and to assess potential population-level impact of the TLC-IDU intervention on Ro, numbers of infections averted, and quality-adjusted life expectancy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •subjects will be adults (≥18 year olds)
- •attend NSP/MARP service sites
- •live in Nairobi (Central Province), Western region, or coastal Mombasa (Coast Province including Malindi), Kenya
- •are IDUs that ever injected any non-prescribed drugs
- •are IDUs that have used any non-prescribed drugs within the past 12 months
- •for HIV viral load testing, individuals must have tested HIV+
- •for HCV viral load testing, individuals must have been confirmed HCV viremic
排除标准
- •subjects are not adults (<18 years old)
- •do not attend NSP/MRP sites
- •do not live in Nairobi (Central Province), Western region, or coastal Mombasa (Coast Province including Malindi), Kenya
- •are not IDUs
- •for viral load testing, individuals who tested HIV-
- •for HCV viral load testing, individuals who were confirmed HCV NOT viremic
研究组 & 干预措施
Control - No intervention
PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
干预措施: HCV+PWID (Drug)
Control - No intervention
PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
干预措施: Control - No intervention (Behavioral)
POC CD4 and Peer Case Management
HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
干预措施: POC CD4 and Peer Case Management (Behavioral)
POC CD4 and Peer Case Management
HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
干预措施: HCV+PWID (Drug)
HCV+PWID
Control and Experimental Confirmed HCV viremic study subject will receive HCV treatment
干预措施: HCV+PWID (Drug)
结局指标
主要结局
Linkage to care and time to ART
时间窗: Data collection done in 5 waves separated by 6 months
Use of rapid CD4 assays to reduce time from HIV diagnosis to ART initiation
Community viral load before and after the TLC-IDU initiation
时间窗: Data collection done in 5 waves separated by 6 months
Community viral load will be ascertained by collecting specimens from randomly-selected HIV-positives at each of the NASCOP NSP-IDU service sites. This sampling will be done in waves over time, to document changes in infectivity (median viral load).
HCV testing and counseling feasibility and acceptability measures
时间窗: Done in wave 6 - 6-month-period
Offering HCV testing and counseling to all study participants. Offering treatment referral for those with HCV monoinfection and HIV-HCV infection
Retention in Care
时间窗: Data collection done in 5 waves separated by 6 months
HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
HCV prevalence determination
时间窗: Data collection done in wave 6 - 6-month-period
Establish HCV prevalence in PWIDs in Nairobi, Western and Coastal region, by adding a rapid HCV assay to the study panel among all participants (both HIV infected and uninfected) recruited during the last TLC-IDU study waves
次要结局
- Modeling HIV transmission dynamics(End of study (will occur in year 5 of the study))
- Assess the incremental cost-effectiveness ratio of the TLC-IDU model(End of study (will occur in year 5 of the study))
